Contact Us
Drug Search Results
More Filters [+]

Casopitant

Alternative Names: casopitant, gw679769
Latest Update: 2024-02-01
Latest Update Note: PubMed Publication

Product Description

Casopitant is a novel NK1 receptor antagonist and second in the class of antiemetics that acts to antagonise the emetogenic effect of substance P. Casopitant has now completed phase III trials for prevention of CINV.  (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697542/)

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Casopitant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Other|Oncology Unspecified|Colorectal Cancer|Lung Cancer

Phase 2: Urinary Incontinence|Dyspepsia|Enuresis|Overactive Bladder|Depressive Disorder, Major|Spinal Cord Injuries|Insomnia|Oncology Unspecified|Anesthesia Related|Fibromyalgia

Phase 1: Healthy Volunteers|Oncology Unspecified|Phobia, Social|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT00891761

P3

Withdrawn

Lung Cancer

2010-07-01

NKV110721

P3

Completed

Colorectal Cancer

2009-04-13

2007-005169-36

P3

Completed

Colorectal Cancer

2009-04-07

NKT102783

P1

Completed

Kidney Diseases

2008-08-22

Recent News Events

Date

Type

Title

02/01/2024

PubMed

 Homology modeling, virtual screening, molecular docking, and ADME approaches to identify a potent agent targeting NK2R protein.

07/01/2022

PubMed

 Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.

11/16/2021

PubMed

 Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions